Director Thomas F. Kearns to resign from FibroGen Board effective June 16, 2022

KYNTRA BIO, INC.

Thomas F. Kearns, Jr. notified resignation from the Board effective June 16, 2022.
Resignation not due to any disagreement with FibroGen's operations, policies or practices.
Kearns served since 1996, including as Chair, Lead Independent Director, and committee chairs.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Thomas F. Kearns, Jr.

Director

KYNB · KYNTRA BIO, INC.

Effective: 2022-06-16
Filed: June 8, 2022, 7:59 PM ET

On June 5, 2022, Thomas F. Kearns, Jr. notified us of his resignation from the Board of Directors (the “Board”) of FibroGen, Inc. (“FibroGen”) effective June 16, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas F. Kearns, Jr. resigned as Director at KYNTRA BIO, INC..

Action: resigned
Role: Director

Exact text from the filing

On June 5, 2022, Thomas F. Kearns, Jr. notified us of his resignation from the Board of Directors (the “Board”) of FibroGen, Inc. (“FibroGen”) effective June 16, 2022.

View on SEC.gov

KYNTRA BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-22-011324

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.